Company / Cash & Equivalents
NRC HEALTH Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$4.1M
FY2025
5-year range
$4.1M / $54.4M
FY2021-FY2025
Trend
-2.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $54M in FY2021 to $4M in FY2025.
Based on SEC 10-K filings.
$4M in FY2025 with a 5-year CAGR of -34.6%.
Declined from $7M to $4M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -45.1%
- 5-Year CAGR
- -34.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- NRC HEALTH's cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of -34.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 2.2% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.1M | -2.2% |
| FY2024 | $4.2M | -36.4% |
| FY2023 | $6.7M | -73.4% |
| FY2022 | $25.0M | -54.0% |
| FY2021 | $54.4M | +56.7% |
| FY2020 | $34.7M | +167.0% |
| FY2019 | $13.0M | -60.7% |
| FY2018 | $33.0M | -21.6% |
| FY2017 | $42.1M | +5.3% |
| FY2016 | $40.0M | +81.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026